Pluristem Therapeutics Inc. (NASDAQ:PSTI) Gears Up For Critical Blood Stem Cell Trial – Market Exclusive
|
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Gears Up For Critical Blood Stem Cell Trial
Market Exclusive The trial will test Pluristem's PLX-R18 placental cells in 30 patients. The cells are designed to repair the hematopoietic (AKA blood) system, in this case the systems of people who have undergone blood stem cell transplants for various reasons but … |
